| Literature DB >> 32455745 |
Abdelmotaleb A Elokil1,2, Khaled F M Abouelezz3, Hafiz I Ahmad4, Yuanhu Pan1, Shijun Li1.
Abstract
The dynamic microbiota in chickens can be affected by exposure to antibiotics, which may alter the composition and substrate availability of functional pathways. Here, 120 Jing Hong chicks at 30 days of age were randomly divided into four treatments totaling seven experimental groups: control chicks not exposed to antibiotics; and chicks exposed to enrofloxacin, diclazuril, and their mixture at 1:1 for 14 days and then not exposed for a withdrawal period of 15 days. Fecal samples were collected from the 7 groups at 8 time-points (exposure to 4 antibiotics and 4 withdrawal periods) to perform in-depth 16S rRNA sequencing of the gut microbiota. Taxon-independent analysis showed that the groups had significantly distinct microbial compositions (p < 0.01). Based on the microbial composition, as compared with the control group, the abundances of the phyla Firmicutes, Actinobacteria, Thermi, and Verrucomicrobia, as well as the families Lactobacillus, Lactococcus, S24-7, and Corynebacterium, were decreased in the antibiotic-exposed chicks (p < 0.01). Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) analyses revealed significant differences in microbiota metabolite pathways due to the genera of the antibiotic-responsive microbes (p < 0.01), especially the pathways relating to cell growth and death, immune system diseases, carbohydrate metabolism, and nucleotide metabolism. Oral treatment with enrofloxacin, diclazuril, and their mixture modified the gut microbiota composition and the microbial metabolic profiles in chickens, with persistent effects (during the withdrawal period) that prevented the return to the original community and led to the formation of a new community.Entities:
Keywords: chicken; diclazuril; enrofloxacin; gut microbiome; metagenomics
Year: 2020 PMID: 32455745 PMCID: PMC7278382 DOI: 10.3390/ani10050896
Source DB: PubMed Journal: Animals (Basel) ISSN: 2076-2615 Impact factor: 2.752
Figure 1Animal experimental design; six experimental groups were obtained as follows: addition of enrofloxacin (ENR-Ad), no enrofloxacin (ENR-Nd), addition of diclazuril (DEC-Ad), no diclazuril (DEC-Nd), addition of drug mixture (MIX-Ad), and no drug mixture (MIX-Nd), while the seventh group was considered the control group.
Relative abundances of fecal microbiota and classification taxa among control and antibiotic-exposed chick groups estimated using the metagenomics analysis.
| Phulum and Genuse 1 | Enrofloxacin (ENR) | Declazuril (DEC) | Mix 1:1 (MIX) | Control | SEM |
| |||
|---|---|---|---|---|---|---|---|---|---|
| ENR.Ad | ENR.Nd | DEC.Ad | DEC.Nd | Mix.Ad | Mix.Nd | CON | |||
|
| 76.840 bc | 73.530 c | 64.880 d | 73.530 c | 50.670 f | 78.740 b | 83.980 a | 1.530 | 0.001 |
|
| 1.960 d | 0.580 f | 0.700 e | 2.170 c | 0.200 g | 2.330 b | 5.520 a | 0.020 | 0.001 |
|
| 0.030 c | 0.012 b | 0.002 c | 0.003 c | 0.020 d | 0.02 d | 0.087 a | 0.000 | 0.001 |
|
| 0.300 a | 0.006 f | 0.300 b | 0.031 e | 0.087 c | 0.061 d | 0.009 g | 0.000 | 0.001 |
|
| 0.040 b | 0.003 c | 0.037 a | 0.007 c | 0.041 a | 0.005 d | 0.029 b c | 0.000 | 0.001 |
|
| 0.060 c | 0.020 e | 0.160 a | 0.05 d | 0.070 b | 0.010f | 0.001 g | 0.001 | 0.001 |
|
| 0.391 d | 0.0567 b | 0.774 a | 0.361 e | 0.480 c | 0.174f | 0.178 f | 0.004 | 0.001 |
|
| 0.005 c | 0.005 c | 0.008 a | 0.007 b | 0.004 c d | 0.003 d | 0.003 d | 0.000 | 0.001 |
|
| 0.179 e | 2.444 a | 0.272 d | 1.850 b | 0.258 d | 1.082 c | 0.183 e | 0.183 | 0.011 |
|
| 10.870 a | 8.120 b | 4.880 b | 7.720 b | 7.080 b | 7.610 b | 11.770 b | 2.260 | 0.090 |
|
| 0.014 c | 0.008 e | 0.009 d | 0.019 b | 0.009 d | 0.009 d | 0.078 a | 0.001 | 0.001 |
|
| 4.590 b | 12.270 a b | 14.840 a | 13.380 a | 7.090 a b | 6.600 a b | 7.760 a b | 2.450 | 0.050 |
|
| 3.970 c | 2.950 d | 3.880 c | 3.690 c | 1.860 e | 4.440 b | 9.910 a | 0.140 | 0.001 |
|
| 0.023 d | 0.007 e | 0.031 c | 0.008 e | 0.002f | 0.310 a | 0.087 b | 0.001 | 0.001 |
|
| 0.0290 c | 0.0140 d | 0.0760 b | 0.0120 e | 0.107 a | 0.008f | 0.001 g | 0.003 | 0.001 |
|
| 0.008 b | 0.006 c | 0.006 c | 0.009 d | 0.006 b | 0.008 b | 0.001 e | 0.000 | 0.001 |
|
| 4.130 b | 4.240 b | 5.430 a | 5.810 a | 4.340 b | 1.510 c | 0.330 d | 1.350 | 0.040 |
|
| 0.112 b | 0.023 c | 0.097 b | 0.077 d | 3.871 a | 0.012 c | 0.003 e | 0.001 | 0.001 |
|
| 0.259 b | 0.025 e | 0.13 b | 0.074 c | 0.339 a | 0.040 d | 0.003 g | 0.000 | 0.050 |
|
| 0.352 b | 0.028 c | 1.030 a | 0.348 b | 0.022 c d | 0.0130 d | 0.016 d | 0.003 | 0.001 |
|
| 0.960 a | 0.560 b | 0.970 a | 0.030f | 0.210 d | 0.340 c | 0.103 e | 0.006 | 0.020 |
|
| 0.008 b | 0.008 b | 0.009 a | 0.001 c | 0.008 b | 0.008 b | 0.008 b | 0.001 | 0.050 |
|
| 0.103 a | 0.062 c | 0.101 b | 0.004 g | 0.009 e | 0.036 d | 0.007 f | 0.001 | 0.001 |
|
| 0.004 c | 0.004 c | 0.289 a | 0.005 c | 0.003 c | 0.103 b | 0.007 c | 0.001 | 0.001 |
|
| 0.009 c | 0.008 e | 0.009 c | 0.008 d | 0.013 a | 0.011 b | 0.005 f | 0.001 | 0.001 |
|
| 0.012 f | 0.017 e | 0.031 b | 0.033 a | 0.021 d | 0.028 c | 0.006 g | 0.002 | 0.001 |
|
| 0.046 b | 0.045 b | 0.046 b | 0.046 b | 0.047 b | 0.045 b | 0.07 a | 0.005 | 0.051 |
|
| 0.008 c | 0.008 d | 0.011 b | 0.006 f | 0.013 a | 0.007 e | 0.008 d | 0.000 | 0.001 |
|
| 0.484 c | 0.007 d | 0.001 d | 1.309 b | 0.004 d | 1.926 a | 0.004 d | 0.020 | 0.001 |
|
| 0.051 c | 0.003 f | 0.002 f | 0.138 b | 0.017 d | 0.204 a | 0.007 e | 0.000 | 0.001 |
|
| 0.498 a | 0.002 g | 0.263 b | 0.043 e | 0.149 d | 0.025 f | 0.190 c | 0.001 | 0.001 |
|
| 0.055 a | 0.002 g | 0.026 b | 0.005 e | 0.016 d | 0.002 f | 0.021 c | 0.000 | 0.001 |
|
| 0.001 b | 0.001 b | 0.004 b | 0.005 b | 0.005 b | 0.004 b | 0.159 a | 0.001 | 0.001 |
|
| 0.006 b | 0.007 b | 0.002 d | 0.004 c | 0.002 d | 0.003 c | 0.016 a | 0.000 | 0.001 |
|
| 0.060 b | 0.034 c | 0.029 d | 0.027 de | 0.024 e | 0.025 e | 0.127 a | 0.001 | 0.050 |
|
| 0.006 b | 0.003 c | 0.003 c | 0.002 d | 0.002 d | 0.002 d | 0.011 a | 0.000 | 0.001 |
1 All data are expressed as the mean ± SEM of the percentage of domain bacteria at taxonomic levels (phylum and family); n = 12 for control group, n = 4 for antibiotic-exposed chicks groups. a,b,c,d Values among groups are significantly different (p < 0.05). ENR-Ad: addition of enrofloxacin; ENR-Nd: no enrofloxacin; DEC-Ad: addition of diclazuril; DEC-Nd: no diclazuril; MIX-Ad: addition of drug mixture; MIX-Nd: no drug mixture; CON: control group.
Observed OTUs and alpha diversity measures of bacterial communities among control and antibiotic-exposed chick groups.
| Alpha Diversity Index | Enrofloxacin (ENR) | Declazuril (DEC) | Mix 1:1 (MIX) | Control | SEM |
| |||
|---|---|---|---|---|---|---|---|---|---|
| ENR-Ad | ENR-Nd | DEC-Ad | DEC-Nd | MIX-Ad | MIX-Nd | CON | |||
| Observed OTUs | 6285.00 a | 4527.25 b | 6302.75 a | 6030.75 a | 4413.50 b | 5451.50 ab | 4115.41 b | 275.54 | 0.001 |
| Simpson | 0.94 a | 0.91 a | 0.96 a | 0.94 a | 0.80 b | 0.94 a | 0.94 a | 0.020 | 0.039 |
| Chao1 | 1516.94 a | 1055.91 cd | 1511.53 a | 1447.44 ab | 1140.58 bcd | 1319.29 abc | 925.53 d | 69.70 | 0.001 |
| ACE | 1579.58 a | 1071.84 bc | 1554.66 a | 1483.48 a | 1166.55 bc | 1331.12 ab | 935.19 d | 70.18 | 0.001 |
| Shannon | 7.24 a | 6.41 ab | 7.64 a | 7.05 a | 5.43 a | 6.87 b | 6.65 ab | 0.270 | 0.048 |
1 All data are expressed as the mean ± SEM of alpha diversity measures; n = 12 for control group, n = 4 for antibiotic-exposed chicks groups. a,b,c,d Values among groups are significantly different (p < 0.05). ENR-Ad: addition of enrofloxacin; ENR-Nd: no enrofloxacin; DEC-Ad: addition of diclazuril; DEC-Nd: no diclazuril; MIX-Ad: addition of drug mixture; MIX-Nd: no drug mixture; CON: control group.
Figure 2(a) Principal component analysis (PCA), (b) nonmetric multidimensional scaling (NMDS), and (c) boxplot for comparative analysis of intergroup–group differences in UniFrac distance pathways among groups of control and antibiotic-exposed chicks. ENR-Ad: addition of enrofloxacin; ENR-Nd: no enrofloxacin; DEC-Ad: addition of diclazuril; DEC-Nd: no diclazuril; MIX-Ad: addition of drug mixture; MIX-Nd: no drug mixture; CON: control group.
Figure 3(a,b) Venn diagram of shared OTUs of the different groups during the period of drug administration (2 weeks) and during the period of no drug administration (2 weeks), respectively. The numbers below the groups indicate the number of OTUs within each sector. (c) Heatmap showing the genera with significant differences in relative abundances among the seven groups. Partial least squares discriminant analysis (PlS-DA) among groups of control and antibiotic-exposed chicks. ENR-Ad: addition of enrofloxacin; ENR-Nd: no enrofloxacin; DEC-Ad: addition of diclazuril; DEC-Nd: no diclazuril; MIX-Ad: addition of drug mixture; MIX-Nd: no drug mixture; CON: control group.
Figure 4Metastat comparison statistics tests; (a) for phylum and (b) for genus among the control group and antibiotic-exposed chick groups.
Phylogenetic investigation of communities by reconstruction of unobserved states (PICRUSt)-predicted analysis of microbial functions based on KEGG pathway groups, control, and antibiotic-exposed chick groups.
| Categories and Levels of KEGG Pathways 1 | The Relative Abundance for Predicting of Functional Microbiome (%) | SEM |
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| ENR-Ad | ENR-Nd | DEC-Ad | DEC-Nd | MIX-Ad | MIX-Nd | CON | |||
|
| |||||||||
| Cell growth and death | 0.51 b | 0.46 b | 0.51 b | 0.48 b | 0.64 a | 0.46 b | 0.45 b | 0.032 | 0.003 |
| Cell motility | 2.63 bc | 3.69 a | 2.38 bc | 2.72 bc | 3.18 ab | 3.01 b | 1.97 c | 0.037 | 0.002 |
| Transport and catabolism | 0.19 b | 0.21 ab | 0.25 ab | 0.23 ab | 0.28 ab | 0.19 b | 0.29 a | 0.028 | 0.023 |
|
| |||||||||
| Membrane transport | 13.49 a | 12.97 a | 12.74 ab | 12.6 ab | 11.06 a | 12.79 ab | 13.73 a | 0.082 | 0.074 |
| Signaling molecules and interaction | 0.19 | 0.17 | 0.18 | 0.19 | 0.19 | 0.19 | 0.18 | 0.016 | 0.973 |
| Signal transduction | 1.69 | 2.06 | 1.82 | 1.89 | 2.02 | 1.94 | 1.64 | 0.146 | 0.132 |
|
| |||||||||
| Folding, sorting, and degradation | 2.33 ab | 2.32 ab | 2.32 ab | 2.36 a | 2.21 a | 2.25 ab | 2.34 ab | 0.043 | 0.041 |
| DNA replication and repair | 8.36 a | 8.04 b | 7.99 bc | 8.34 ab | 7.89 b | 8.35 a | 6.92 c | 0.348 | 0.021 |
| Transcription | 2.86 | 2.74 | 2.68 | 2.71 | 2.74 | 2.91 | 2.76 | 0.094 | 0.601 |
| Translation | 5.41 ab | 5.16 ab | 5.17 ab | 5.37 ab | 4.73 b | 5.33 ab | 5.69 a | 0.283 | 0.035 |
|
| |||||||||
| Immune system diseases | 0.06 a | 0.05 a | 0.05 a | 0.06 a | 0.04 b | 0.05 ab | 0.06 a | 0.004 | 0.004 |
| Infectious diseases | 0.42 a | 0.44 a | 0.41 ab | 0.43 a | 0.47 a | 0.44 a | 0.4 b | 0.021 | 0.049 |
| Metabolic diseases | 0.09 ab | 0.09 b | 0.08 b | 0.08 b | 0.08 b | 0.09 ab | 0.11 a | 0.006 | 0.002 |
| Neurodegenerative diseases | 0.17 b | 0.22 b | 0.23 b | 0.22 b | 0.44 a | 0.17 b | 0.16 b | 0.050 | 0.004 |
|
| |||||||||
| Amino acid metabolism | 9.56 ab | 9.91 ab | 9.95 ab | 9.74 ab | 10.49 a | 9.30 b | 9.35 b | 0.364 | 0.043 |
| Biosynthesis of secondary metabolites | 0.81 b | 0.78 b | 0.77 b | 0.73 b | 0.96 a | 0.76 b | 0.79 b | 0.040 | 0.012 |
| Carbohydrate metabolism | 10.53 ab | 9.73 c | 10.38 abc | 9.98 bc | 10.4 abc | 10.17 bc | 10.92 a | 0.244 | 0.003 |
| Energy metabolism | 5.35 ab | 5.3a b | 5.36 ab | 5.27 ab | 5.55 a | 5.17 b | 5.41 ab | 0.094 | 0.061 |
| Enzyme families | 2.13 | 2.03 | 1.96 | 2.01 | 2.01 | 2.11 | 2.15 | 0.069 | 0.199 |
| Glycan biosynthesis and metabolism | 1.55 b | 1.55 b | 1.66 ab | 1.68 ab | 1.41 b | 1.56 b | 1.92 a | 0.110 | 0.005 |
| Lipid metabolism | 3.07 b | 3.2 ab | 3.5 ab | 3.41 a b | 3.63 a | 3.03 b | 3.14 ab | 0.168 | 0.089 |
| Cofactors and vitamins | 4.00 | 4.05 | 3.93 | 3.92 | 4.08 | 3.98 | 3.97 | 0.120 | 0.953 |
| Other amino acids | 1.67 ab | 1.67 ab | 1.78 ab | 1.71 ab | 1.93 a | 1.61 b | 1.62 b | 0.086 | 0.025 |
| Terpenoids and polyketides | 1.86 ab | 1.85 ab | 2.06 a | 1.99 ab | 2.09 a | 1.74 b | 1.75 b | 0.097 | 0.028 |
| Nucleotide metabolism | 3.95 a b | 3.71 b | 3.67 b | 3.88 a b | 3.42 b | 3.87 a b | 4.26 a | 0.171 | 0.005 |
| Xenobiotic biodegradation | 3.62 a | 3.63 a | 3.28 b | 3.01 c | 3.03 c | 2.42 d | 2.49 cd | 0.302 | 0.047 |
|
| |||||||||
| Circulatory system | 0.01 b | 0.02 ab | 0.02 b | 0.02 b | 0.04 a | 0.01 b | 0.01 b | 0.007 | 0.018 |
| Digestive system | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.005 | 0.139 |
| Endocrine system | 0.25 b | 0.25 b | 0.30 b | 0.25 b | 0.4 a | 0.23 b | 0.26 b | 0.032 | 0.015 |
| Excretory system | 0.04 ab | 0.03 ab | 0.03 ab | 0.04 a | 0.03 b | 0.03 ab | 0.03 ab | 0.004 | 0.032 |
| Immune system | 0.06 | 0.06 | 0.05 | 0.05 | 0.04 | 0.06 | 0.05 | 0.007 | 0.609 |
| Nervous system | 0.09 b | 0.09 ab | 0.08 b | 0.09 b | 0.08 b | 0.09 b | 0.11 b | 0.005 | 0.001 |
1 All data are expressed as the mean ± SEM of the relative abundance for prediction of the functional microbiomes; a,b,c,d values among groups are significantly different (p <0.05). ENR-Ad: addition of enrofloxacin; ENR-Nd: no enrofloxacin; DEC-Ad: addition of diclazuril; DEC-Nd: no diclazuril; MIX-Ad: addition of drug mixture; MIX-Nd: no drug mixture; CON: control group.